Vitamin K2: MK-7 vs MK-4 Clinical Differences and Optimal Form Selection

Vitamin K2 exists in multiple forms, yet most consumers and many practitioners remain unaware that the choice between menaquinone-7 (MK-7) and menaquinone-4 (MK-4) carries significant clinical implications. These two forms differ fundamentally in their pharmacokinetics, tissue distribution, dosing requirements, and evidence base for specific health outcomes.

The distinction matters because MK-7 and MK-4 are not interchangeable at equivalent doses. Their structural differences translate to vastly different serum half-lives, bioavailability profiles, and optimal dosing protocols. Understanding these differences enables evidence-based selection for bone mineralization, arterial health, and synergistic vitamin D supplementation.

What is Vitamin K2?

Vitamin K2, or menaquinone, represents a family of fat-soluble compounds characterized by a common naphthoquinone ring structure with varying isoprenoid side chains. While vitamin K1 (phylloquinone) functions primarily in hepatic coagulation factor synthesis, vitamin K2 serves as a cofactor for gamma-glutamyl carboxylase, the enzyme that activates vitamin K-dependent proteins throughout extrahepatic tissues.

The number in the menaquinone designation (MK-4, MK-7, MK-9) indicates the number of isoprenoid units in the side chain. This seemingly minor structural variation profoundly affects lipid solubility, membrane incorporation, cellular uptake, and elimination kinetics. MK-4 contains four isoprenoid units and is the form produced endogenously from K1 conversion, though this conversion is inefficient in humans. MK-7 contains seven isoprenoid units and is produced exclusively by bacterial fermentation, most notably in natto, a traditional Japanese fermented soybean product.

Beyond their structural chemistry, these menaquinones activate matrix Gla protein (MGP) in arterial tissue and osteocalcin in bone, proteins that require carboxylation to function. Undercarboxylated forms of these proteins associate with vascular calcification and reduced bone mineral density, establishing the mechanistic basis for K2's role in calcium metabolism regulation.

What is Vitamin K2 Used For?

Vitamin K2 supplementation addresses two primary clinical objectives: optimizing bone mineralization and preventing soft tissue calcification, particularly in arterial walls. These applications stem from K2's unique role in activating proteins that direct calcium to appropriate tissues while preventing its deposition in inappropriate locations.

• Bone mineral density support: Activation of osteocalcin, the primary non-collagenous protein in bone matrix, which binds calcium and hydroxyapatite to promote mineralization
• Arterial health: Carboxylation of matrix Gla protein, an inhibitor of vascular calcification that prevents calcium deposition in arterial walls
• Vitamin D synergy: Complementary action with vitamin D3, which upregulates vitamin K-dependent protein production but does not activate them, creating functional demand for K2
• Cardiovascular risk reduction: Associated with reduced arterial stiffness and coronary calcification in populations with adequate intake
• Fracture risk reduction: Long-term supplementation studies show associations with reduced vertebral and hip fracture incidence in postmenopausal women

The clinical applications extend beyond these primary uses to include potential roles in glucose metabolism, though evidence remains preliminary. The therapeutic focus centers on conditions where calcium distribution dysregulation contributes to pathology, particularly osteoporosis concurrent with vascular disease, a common but paradoxical presentation.

Evidence and Mechanisms: MK-7 vs MK-4 Differences

Pharmacokinetic Profiles

The fundamental distinction between MK-7 and MK-4 lies in their pharmacokinetic behavior. Schurgers and colleagues demonstrated that MK-7 achieves maximal serum concentration 6 hours post-ingestion with a half-life of approximately 72 hours, while MK-4 peaks within 2 hours but has a half-life of only 1-2 hours [1]. This translates to dramatically different steady-state kinetics and dosing requirements.

MK-7 supplementation at 180 mcg daily achieves stable serum concentrations with once-daily dosing, while equivalent MK-4 dosing results in negligible serum accumulation due to rapid elimination.

Bioavailability studies using stable isotope tracers reveal that MK-7 demonstrates 3-fold higher area-under-curve values compared to MK-4 at identical doses [2]. The longer isoprenoid side chain of MK-7 enhances incorporation into lipoproteins, particularly LDL and VLDL, facilitating sustained circulation and tissue delivery. MK-4's shorter chain reduces lipoprotein binding affinity, accelerating hepatic uptake and biliary excretion.

• MK-7 half-life: 72-96 hours, enabling once-daily dosing
• MK-4 half-life: 1-2 hours, necessitating multiple daily doses or supraphysiological amounts
• Serum stability: MK-7 maintains therapeutic concentrations 24 hours post-dose; MK-4 returns to baseline within 6-8 hours
• Tissue accumulation: MK-7 shows preferential accumulation in extrahepatic tissues over 7-14 days; MK-4 demonstrates minimal extrahepatic retention at nutritional doses

Clinical Evidence for Bone Health

The bone health evidence diverges significantly between forms, largely reflecting their different dosing paradigms. Japanese studies using MK-4 at pharmacological doses (45 mg daily, approximately 150-fold higher than typical MK-7 doses) demonstrate reduced fracture incidence in osteoporotic populations [3]. These studies established MK-4 as an approved osteoporosis treatment in Japan, though the doses employed far exceed nutritional supplementation ranges.

MK-7 research focuses on nutritional doses (90-360 mcg daily) achievable through supplementation. The Rotterdam Study, a population-based cohort, found that dietary MK-7 intake inversely correlated with coronary calcification and cardiovascular mortality, while K1 and MK-4 showed no association [4]. Intervention trials using MK-7 at 180 mcg daily demonstrate improved carboxylation of osteocalcin and MGP within 12 weeks [5].

• MK-4 fracture trials: 45 mg daily reduced vertebral fractures 52% and hip fractures 73% over 3 years in Japanese osteoporotic women
• MK-7 bone density trials: 180 mcg daily improved lumbar spine BMD and reduced undercarboxylated osteocalcin 50-70% in postmenopausal women